<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Safouris A</dc:creator>
  <dc:creator>Katsanos AH</dc:creator>
  <dc:creator>Kerasnoudis A</dc:creator>
  <dc:creator>Krogias C</dc:creator>
  <dc:creator>Kinsella JA</dc:creator>
  <dc:creator>Sztajzel R</dc:creator>
  <dc:creator>Lambadiari V</dc:creator>
  <dc:creator>Deftereos S</dc:creator>
  <dc:creator>Kargiotis O</dc:creator>
  <dc:creator>Sharma VK</dc:creator>
  <dc:creator>Demchuk AM</dc:creator>
  <dc:creator>Saqqur M</dc:creator>
  <dc:creator>McCabe DJH</dc:creator>
  <dc:creator>Tsivgoulis G</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Background and Purpose- Scarce data indicate that statin pretreatment (SP) in patients with acute cerebral ischemia because of large artery atherosclerosis may be related to lower risk of recurrent stroke because of a decreased incidence of microembolic signals (MES) during transcranial Doppler monitoring. Methods- We performed a systematic review and meta-analysis of available observational studies reporting MES presence/absence or MES burden, categorized according to SP status, in patients with acute cerebral ischemia because of symptomatic (≥50%) large artery atherosclerosis. In studies with partially-published data, authors were contacted for previously unpublished information. We also performed a sensitivity analysis of studies with data on MES burden categorized according to SP status, and an additional subgroup analysis in patients receiving higher-dose SP (atorvastatin 80 mg or rosuvastatin 40 mg daily). Results- Seven eligible study protocols were identified (610 patients, 54% with SP). SP was associated with a reduced risk of MES detection during transcranial Doppler monitoring (risk ratio=0.67; 95% CI, 0.45-0.98), with substantial heterogeneity between studies ( I2=52%). In studies reporting MES burden (n=4), a significantly lower number of MES were identified in patients with compared with those without SP (mean difference=-0.92; 95% CI, -1.64 to -0.19), with no evidence of heterogeneity between studies ( I2=49%). Subgroup analysis revealed that higher-dose SP reduced the risk of detecting MES (risk ratio=0.23; 95% CI, 0.06-0.88), with no evidence of heterogeneity between studies ( I2=0%). Conclusions- SP seems to be associated with a lower incidence and burden of MES in patients with acute cerebral ischemia because of large artery atherosclerosis.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/242709</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1161/STROKEAHA.118.021542</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29991656</dc:relation>
  <dc:source>Stroke. - 2018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">atherosclerosis</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">carotid stenosis</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">cerebral embolism</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">statins</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">transcranial doppler sonography</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Brain Ischemia</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Hydroxymethylglutaryl-CoA Reductase Inhibitors</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Intracranial Arteriosclerosis</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Intracranial Embolism</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Microvessels</dc:subject>
  <dc:title xmlns:ns12="xml" ns12:lang="en">Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
